Table 1.
Results of the primary outcome variables among the Group A (PVP-I 0.6% eye drops 4 times/daily for 20 days) and B (hyaluronate-based tear substitutes 4 times/daily for 20 days).
| Corneal Haze (percentage of absence) | Chemosis (grade 0) | Injection (grade 0) | Infiltrates (n = 0) | Pain (grade 0) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up assessments | Group A (n = 34) Freq/% |
Group B (n = 25) Freq/% |
p value | Group A (n = 34) Freq/% |
Group B (n = 25) Freq/% |
p value | Group A (n = 34) Freq/% |
Group B (n = 25) Freq/% |
p value | Group A (n = 34) Freq/% |
Group B (n = 25) Freq/% |
p value | Group A (n = 34) Freq/% |
Group B (n = 25) Freq/% |
p value |
| T0 | 20/34 | 14/25 | 0.828 | 18/34 | 7/25 | 0.061 | 0/34 | 0/25 | 0.109 | 21/34 | 13/25 | 0.277 | 0/34 | 0/25 | 0.118 |
| T2 ds | 18/34 | 15/25 | 0.589 | 18/34 | 7/25 | 0.061 | 1/34 | 0/25 | 0.122 | 21/34 | 11/25 | 0.322 | 0/34 | 0/25 | 0.993 |
| T4 ds | 19/34 | 17/25 | 0.611 | 21/34 | 9/25 | 0.120 | 1/34 | 0/25 | 0.122 | 22/34 | 11/25 | 0.180 | 0/34 | 0/25 | 0.911 |
| T6 ds | 22/34 | 18/25 | 0.775 | 24/34 | 19/25 | 0.061 | 2/34 | 1/25 | 0.047* | 21/34 | 10/25 | 0.195 | 0/34 | 0/25 | 0.599 |
| T8 ds | 22/34 | 18/25 | 0.775 | 24/34 | 19/25 | 0.061 | 16/34 | 7/25 | 0.197 | 21/34 | 10/25 | 0.195 | 0/34 | 0/25 | 0.599 |
| T10 ds | 28/34 | 21/25 | 0.528 | 32/34 | 15/25 | 0.005* | 16/34 | 7/25 | 0.197 | 23/34 | 11/25 | 0.283 | 1/34 | 0/25 | 0.802 |
| T15 ds | 34/34 | 22/25 | 0.038* | 33/34 | 19/25 | 0.013* | 23/34 | 11/25 | 0.069 | 23/34 | 11/25 | 0.050* | 5/34 | 1/25 | 0.011* |
| T21 ds | 34/34 | 23/25 | 0.213 | 34/34 | 22/25 | 0.038* | 31/34 | 17/25 | 0.024* | 31/34 | 14/25 | 0.005* | 9/34 | 2/25 | 0.010* |
The values marked by the asterisk * are statistically significant.